Targeting H3.3 mutations in pediatric HGG
Brendan D. Price, Ph.D., Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA First–Year Funding Summary, going into the second-year Pediatric high-grade gliomas (pHGG) have few treatment options and most children diagnosed only survive for 1-2 years. Identifying new treatments is therefore of the highest priority. Work in the lab is focused …